0002007997-24-000006.txt : 20240412 0002007997-24-000006.hdr.sgml : 20240412 20240412180126 ACCESSION NUMBER: 0002007997-24-000006 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240402 FILED AS OF DATE: 20240412 DATE AS OF CHANGE: 20240412 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ramaswamy Vivek CENTRAL INDEX KEY: 0001635075 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 24842613 MAIL ADDRESS: STREET 1: C/O ONCORE BIOPHARMA, INC. STREET 2: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 FORMER NAME: FORMER CONFORMED NAME: Ramasawamy Vivek DATE OF NAME CHANGE: 20150226 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 3 1 primary_doc.xml PRIMARY DOCUMENT X0206 3 2024-04-02 0 0001635088 Roivant Sciences Ltd. ROIV 0001635075 Ramaswamy Vivek P.O. BOX 20860 COLUMBUS OH 43220 0 0 1 0 Common Shares 53431426 D Stock Option (Right to Buy) 12.68 2026-03-31 Common Shares 21856138 D Stock Option (Right to Buy) 13.78 2026-03-31 Common Shares 1753905 D Stock Option (Right to Buy) 15.85 2026-03-31 Common Shares 5915052 D Capped Value Appreciation Rights 11.5 2026-03-31 Common Shares 11570769 D Reflects an award of stock options to purchase Common Shares that is fully vested. Reflects a fully service-vested award of capped value appreciation rights ("CVARs") that, upon achievement of the hurdle price condition based on the hurdle price reflected in column 4 of Table II above on an applicable measurement date, entitle the reporting person to an amount equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of a Common Share (capped at $12.68 per share) as of the relevant date of determination over (B) the hurdle price reflected in column 4 of Table II above (such excess, the "CVAR Amount"). The CVARs will be settled in a number of Common Shares determined by dividing (i) the applicable CVAR Amount by (ii) the fair market value of a Common Share as of the applicable payment date. The reporting person became a 10% shareholder of the Issuer following the repurchase of Common Shares announced by the Issuer on April 2, 2024 and not through any transaction by the reporting person. By: /s/ Stephen Roberts, as Attorney-in-Fact for Vivek Ramaswamy 2024-04-12 EX-24 2 vrpa_sr.txt POWEROFATTORNEY GRANT OF LIMITED POWER OF ATTORNEY I, Vivek Ramaswamy, of Columbus, Ohio, do hereby make, constitute, and appoint Stephen Roberts, of Alexandria, Virginia, my true and lawful attorney-in-fact for me and in my name, place, and stead, and on my behalf, and for my use and benefit authorizing him: 1 To execute in my name any documents required for the receipt, vesting, or purchase of shares of any equity instruments (to include common shares, stock options, warrants, grants, and capped value appreciation rights), and any documents required for the reporting or acknowledgment of the same; and 2 To execute in my name any documents required to complete sell-to-cover transactions associated with the transactions described in Paragraph 1 of this Grant. This Grant shall continue in effect until I revoke it by separate written instrument. /s/ Vivek Ramaswamy Signature 8/21/2023 Date